Genetron Holdings Ltd represents values of innovation, integrity, and collaboration. With a corporate philosophy centered on advancing precision oncology through technology, Genetron is dedicated to transforming cancer diagnosis and treatment. The company strives to improve patient outcomes by developing and commercializing cutting-edge molecular profiling assays and solutions. Through its comprehensive genomic testing platforms, Genetron aims to empower physicians and researchers to make informed decisions for personalized cancer care. By leveraging its expertise in next-generation sequencing and advanced data analysis, Genetron is committed to driving advancements in precision medicine and contributing to the global fight against cancer.

Genetron Holdings Ltd is primarily present in China.

Genetron Holdings Ltd, a renowned company in the field of genomics and precision oncology, has achieved remarkable milestones throughout its journey. Firstly, the company successfully developed the Genetron S5, an innovative sequencing system, enabling high-quality genetic testing and analysis for cancer patients. Secondly, Genetron Holdings established strategic collaborations with reputable medical institutions, such as the Mayo Clinic and the China National Cancer Center, enhancing their research capabilities and expanding their market influence. Additionally, the company obtained the CE-IVD marking for multiple molecular diagnostic products, enabling their use in European clinical practice. Furthermore, Genetron Holdings gained recognition by receiving numerous awards, including the Frost & Sullivan 2021 Best Practices Award for Chinese Next-Generation Sequencing Solutions Company of the Year. These milestones exemplify the company's commitment to revolutionizing cancer diagnosis and treatment through cutting-edge genomics technology.

Genetron Holdings Ltd is a prominent biotechnology company that specializes in precision oncology. Founded in 2015, the company has quickly gained recognition for its innovative approach to cancer treatment. As a leading player in the field, Genetron has developed advanced molecular profiling technology and diagnostic solutions to aid in personalized cancer care. With a team consisting of experienced professionals, Genetron focuses on harnessing the power of genomics to revolutionize cancer treatment and improve patient outcomes. By leveraging cutting-edge technologies and strategic collaborations, Genetron Holdings Ltd continues to make significant contributions to the field of precision medicine.

The main competitors of Genetron Holdings Ltd in the market include Illumina Inc., Thermo Fisher Scientific Inc., and Qiagen N.V.

Genetron Holdings Ltd is primarily active in the healthcare and biotechnology industries.

Genetron Holdings Ltd is a leading precision oncology company that focuses on providing innovative solutions for cancer diagnosis and treatment. The company's business model revolves around its advanced molecular profiling technology, which enables personalized cancer therapy and enables better patient outcomes. By utilizing cutting-edge techniques such as next-generation sequencing and artificial intelligence, Genetron Holdings Ltd aims to revolutionize cancer care by offering accurate and reliable genomic profiling services. Through its comprehensive portfolio of products and services, the company is committed to empowering healthcare professionals with actionable insights to make informed treatment decisions and improve patient care.

Genetron Holdings hissesinin F/K oranı -11,59.

Genetron Holdings KUV 4,97 dir.

Genetron Holdings için AlleAktien Kalite Skoru 4/10'dur.

beklenen Genetron Holdings cirosu 904,47 Milyon. CNY dir.

beklenen Genetron Holdings karı -388,35 Milyon. CNY olarak gerçekleşmiştir.

Genetron Holdings Ltd is a China-based company specialized in the development of precision medicine products and services. The company offers a variety of solutions for clinicians, researchers, and medical institutions. Genetron operates in three business segments: Liquid Biopsy, Oncology Testing Services, and Cancer Genomics. Liquid Biopsy: Genetron's Liquid Biopsy business segment provides a non-invasive method for detecting cancer cells through liquid biopsies. The company has a proprietary technology platform for examining minimal residual disease in patients. This technology is used to examine biological materials such as blood and urine for cancer cells and other cellular irregularities. The results are then used for diagnosis and disease monitoring. Oncology Testing Services: Genetron's Oncology Testing Services enable doctors to create personalized treatment plans for cancer patients. The company offers a wide range of testing services, including whole exome sequencing, RNA sequencing, genome-wide methylation analysis, and protein analysis. The company utilizes next-generation technologies to identify and characterize the molecular features of cancer cells. These tests help doctors create tailored treatment plans based on the specific genetic differences of each patient. Cancer Genomics: Genetron is a leading provider of cancer genomics technologies and services. The company offers a range of solutions that enable researchers and medical institutions to collect and analyze cancer genomic data. The company's core technologies include whole exome sequencing, transcriptome sequencing, and splice variant sequencing. These technologies allow researchers to identify and characterize the molecular features of cancer cells. The results of these analyses are used to develop personalized treatment options and explore new therapies. Summary: Overall, Genetron Holdings Ltd offers a comprehensive range of products and services in the field of precision medicine. The company is a leader in Liquid Biopsy, Oncology Testing Services, and Cancer Genomics. Genetron's technologies and services enable doctors and researchers to identify, characterize, and develop personalized treatment options for cancer cells. The company is well-positioned to benefit from the growing demand for precision medicine products and services.

Genetron Holdings, yılda kez dağıtılmak üzere 0 CNY tutarında temettü ödemektedir.

Genetron Holdings için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Genetron Holdings şirketinin ISIN kodu US37186H1005’dir.

Genetron Holdings 'nin WKN'si A2P661 'dir.

Genetron Holdings için Ticker GTH’dir.

Son 12 ay içerisinde Genetron Holdings, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Genetron Holdings, tahmini olarak 0 CNY tutarında bir temettü ödemesi yapacak.

Genetron Holdings şirketinin mevcut temettü verimi .

Genetron Holdings dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Genetron Holdings, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 CNY tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Genetron Holdings, 'Sağlık' sektörüne atanmıştır.

Son Genetron Holdings tarihinde 0 CNY tutarındaki en son temettüyü alabilmek için, hisseyi 09.09.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 09.09.2024 olarak gerçekleşti.

2023 yılında Genetron Holdings tarafından 0 CNY olarak temettüler dağıtıldı.

Genetron Holdings hisselerinin temettüleri CNY olarak dağıtılır.